Aktien Sensor

Merck & Co. has partnered with Danish biotech firm Evaxion A/S to develop and commercialize Evaxion’s vaccine candidate EVX-B3, with the potential to generate significant milestone payments and royalty income as the global vaccine market is projecte…

Merck & Co Inc has announced positive results from a Phase 3 trial of its lipid therapy, Enlicitide Decanoate, which demonstrated its efficacy in lowering LDL cholesterol in patients with hypercholesterolemia.

Merck & Co Inc’s stock remains steady, poised for growth as the demand for minimal residual disease testing increases due to rising cancer cases and advancements in molecular diagnostics.

Merck & Co Inc has demonstrated resilience in a turbulent market, impressing analysts with its strong performance and well-positioned business model.

Merck & Co Inc’s stock price remains stable, with investors awaiting the company’s quarterly financial report for insight into its current performance and future prospects.

Merck & Co Inc. has unveiled a comprehensive restructuring plan to address declining sales and profits, aiming to save $3 billion annually and redirect funds towards growth areas and new medicine development.

Merck & Co Inc is expected to report a decline in earnings per share for the fourth quarter, amidst market fluctuations and industry challenges.

Merck & Co Inc is set to release its quarterly earnings on July 29, 2025, amidst a growing pharmaceutical industry driven by innovation in cancer research and treatment.

Merck & Co Inc is a promising investment opportunity due to its focus on cancer research and development of targeted treatments, driven by a growing demand for effective cancer therapies.

Merck & Co Inc has made a significant investment in a $1 billion biologics hub to boost KEYTRUDA production, but the pharmaceutical sector’s long-term prospects remain uncertain due to revived drug pricing policies.